Renovis, Pfizer to collaborate on pain research

South San Francisco-based Renovis has inked a deal to collaborate with Pfizer on research into the VR1 receptor that could be worth up to $170 million. Renovis will gain a $10 million licensing fee and $7 million in research money for the next two years. The two companies will focus on developing an inhibitor on VR1, a protein that plays a role in inflicting pain.

- read this article from MSN for more on the deal

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.